Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.

被引：0
|
作者：
Kaseb, Ahmed Omar [1 ]
Pestana, Roberto Carmagnani [1 ]
Vence, Luis M. [1 ]
Blando, Jorge M. [1 ]
Singh, Shalini [1 ]
Ikoma, Naruhiko [1 ]
Vauthey, Jean-Nicolas [1 ]
Allison, James Patrick [1 ]
Sharma, Padmanee [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期
关键词：
D O I：
10.1200/JCO.2019.37.8_suppl.52
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
52
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients with previously untreated unresectable or metastatic urothelial carcinoma (CheckMate 901)
    Waller, C. F.
    Galsky, M. D.
    Powles, T.
    van der Heijden, M. S.
    Li, S.
    Hennicken, D.
    Sonpavde, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 324 - 325
  • [22] An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)
    Hodi, F. S.
    Gibney, G.
    Sullivan, R.
    Sosman, J. A.
    Slingluff, C. L., Jr.
    Lawrence, D. P.
    Logan, T. F.
    Schuchter, L. M.
    Nair, S.
    Fecher, L.
    Buchbinder, E.
    Ruisi, M.
    Kong, G.
    Horak, C.
    Weber, J. S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S721 - S721
  • [23] Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
    Tanizaki, J.
    Yonemori, K.
    Akiyoshi, K.
    Minami, H.
    Ueda, H.
    Takiguchi, Y.
    Miura, Y.
    Segawa, Y.
    Takahashi, S.
    Iwamoto, Y.
    Kidera, Y.
    Fukuoka, K.
    Ito, A.
    Chiba, Y.
    Sakai, K.
    Nishio, K.
    Nakagawa, K.
    Hayashi, H.
    ANNALS OF ONCOLOGY, 2022, 33 (02) : 216 - 226
  • [24] CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
    Schenker, Michael
    Burotto, Mauricio
    Richardet, Martin
    Ciuleanu, Tudor
    Goncalves, Anthony
    Steeghs, Neeltje
    Schoffski, Patrick
    Ascierto, Paolo A.
    Maio, Michele
    Lugowska, Iwona
    Lupinacci, Lorena
    Leary, Alexandra
    Delord, Jean-Pierre
    Grasselli, Julieta
    Tan, David S.
    Friedmann, Jennifer E.
    Vuky, Jacqueline
    Tschaika, Marina
    Slepetis, Ruta
    Kollia, Georgia D.
    Pacius, Misena
    Huang, Ning
    Doshi, Parul
    Baden, Jonathan
    Di Nicola, Massimo
    CANCER RESEARCH, 2022, 82 (12)
  • [25] A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST).
    Singh, Arun S.
    Chmielowski, Bartosz
    Hecht, J. Randolph
    Rosen, Lee S.
    Chow, Warren Allen
    Wang, Xiaoyan
    Brackert, Sandra
    Adame, Carlos
    Bovill, John
    Schink, Elena
    Douek, Michael
    Chantharasamee, Jomjit
    Wong, Karlton
    Eilber, Frederick C.
    Glaspy, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.
    Shah, Manish A.
    Metges, Jean-Philippe
    Chun, Patrick Youngwhan
    Smith, Victoria
    Maltzman, Julia D.
    Wainberg, Zev A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors
    Singh, Arun S.
    Hecht, J. Randolph
    Rosen, Lee
    Wainberg, Zev A.
    Wang, Xiaoyan
    Douek, Michael
    Hagopian, Anahis
    Andes, Rachel
    Sauer, Lauren
    Brackert, Sandra R.
    Chow, Warren
    DeMatteo, Ronald
    Eilber, Fritz Christian
    Glaspy, John A.
    Chmielowski, Bartosz
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 84 - 94
  • [28] Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
    Andre, Thierry
    Elez, Elena
    Lenz, Heinz-Josef
    Jensen, Lars Henrik
    Touchefeu, Yann
    Van Cutsem, Eric
    Garcia-Carbonero, Rocio
    Tougeron, David
    Mendez, Guillermo Ariel
    Schenker, Michael
    de la Fouchardiere, Christelle
    Limon, Maria Luisa
    Yoshino, Takayuki
    Li, Jin
    Mozo, Jose Luis Manzano
    Dahan, Laetitia
    Tortora, Giampaolo
    Chalabi, Myriam
    Goekkurt, Eray
    Braghiroli, Maria Ignez
    Joshi, Rohit
    Cil, Timucin
    Aubin, Francine
    Cela, Elvis
    Chen, Tian
    Lei, Ming
    Jin, Lixian
    Blum, Steven, I
    Lonardi, Sara
    LANCET, 2025, 405 (10476): : 383 - 395
  • [29] A RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (GBM)
    Ahluwalia, Manmeet
    Fallah, Jaleh
    Peereboom, David
    Schilero, Cathy
    Ali, Assad
    Forst, Deborah
    Wong, Eric
    Wen, Patrick
    Reardon, David
    NEURO-ONCOLOGY, 2019, 21 : 220 - 220
  • [30] RANDOMIZED PHASE II OPEN-LABEL STUDY OF NIVOLUMAB PLUS STANDARD-DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW-DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM): FINAL REPORT
    Ahluwalia, Manmeet
    Khosla, Atulya
    Rauf, Yasmeen
    Peereboom, David
    Wen, Patrick Y.
    Reardon, David A.
    NEURO-ONCOLOGY, 2022, 24 : 64 - 64
12345